Trial Profile
A 26-week Trial Investigating the Dosing Flexibility, Efficacy and Safety of NN1250 in Subjects With Type 1 Diabetes With a 26-week Extension (Begin: Flex T1)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Insulin degludec (Primary) ; Insulin aspart; Insulin glargine
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms BEGIN
- Sponsors Novo Nordisk
- 05 Oct 2012 Extension study results presented at the 48th Annual Meeting of the European Association for the Study of Diabetes.
- 05 Oct 2012 Results comparing efficacy and tolerability of the 2 insulin degludec dosing regimens presented at the 48th Annual Meeting of the European Association for the Study of Diabetes.
- 16 Mar 2012 Actual end date changed from May 2011 to Mar 2012 as reported by European Clinical Trials Database.